Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge
Diabetes Obesity and Metabolism2020Vol. 22(11), pp. 1985–1994
Citations Over TimeTop 16% of 2020 papers
Brian E. Ford, Shruti S. Chachra, Ahmed Alshawi, Alfie Brennan, Suzannah J. Harnor, Céline Cano, David Baker, David M. Smith, Rebecca J. Fairclough, Loranne Agius
Abstract
Chronic GKA treatment of C57BL/6 mice for 8 weeks activates liver ChREBP and improves the resilience of hepatocytes to compromised ATP homeostasis during high-substrate challenge. These changes are associated with raised mRNA levels of ChREBP-β and both catalytic subunits of AMP-activated protein kinase.
Related Papers
- → Liver glucokinase: An overview on the regulatorymechanisms of its activity(2011)118 cited
- → Small Molecule Glucokinase Activators as Glucose Lowering Agents: A New Paradigm for Diabetes Therapy(2006)71 cited
- → Characterization of a Novel Glucokinase Activator in Rat and Mouse Models(2014)19 cited
- → Glucokinase and glucokinase regulatory proteins as molecular targets for novel antidiabetic drugs(2015)3 cited
- → Глюкокиназа и белок-регулятор глюкокиназы как молекулярные мишени для создания новых противодиабетических препаратов(2015)2 cited